Avsnitt
-
Tom Hale, CEO of ŌURA, joins Vijay Pande, founding partner, and Daisy Wolf, investment partner at a16z Bio + Health.
Together, they talk about the potential of wearables to change behavior, and how that can affect health. They also discuss how AI could maximize the usefulness of wearables and power the insights provided to wearers.
-
Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.
Together, they discuss the transformative power of drugs in changing human health—and history. They also reflect on the evolution of the drug discovery process as it shifts from serendipitous discovery to AI-enabled engineering. Finally, they chat about where the industry is headed, and how AI might change the competition landscape.
-
Saknas det avsnitt?
-
Vijay Pande, founding general partner of a16z Bio + Health, chats with the builders (and siblings) behind Devoted Health, Ed and Todd Park.
The Park brothers, with decades of expertise in healthcare and policy, including as EVP and COO at athenahealth (Ed) and Chief Technology Officer of the United States (Todd), started Devoted with the idea of building a healthcare model from scratch. Together, their discussion underscores the sector's urgent need for technological innovation and the game-changing role of AI.
This episode was recorded live at a16z's LP Summit.
-
Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today.
The discussion covers the implications of AI integration in healthcare workflows, AI as a potential catalyst for value-based care, and the potential for innovation in clinical trials. They also talk about the AI startup they each wish would walk through the door.
-
Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS), joins a16z Bio + Health general partner Jorge Conde.
Together, they talk about how AI could transform drug discovery and development at a large biopharma company—and how a company might have to adapt to harness AI; modalities they’re excited about; and Greg’s do’s and don’ts for startups looking to partner with a company like BMS.
-
As any healthcare founder knows, it can be difficult to get into a room with the executives making purchase decisions for payors and providers—so we’re bringing the executives to you.
This episode features interviews with payor and provider leaders about what they’re seeing and how they’re thinking about AI. Guided by Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, you'll hear from the executives about how they're utilizing AI, the KPIs they use to gauge effectiveness, and what they consider a good partnership.
Julie and Jay also authored an in-depth guide to commercializing AI in healthcare based on these interviews, available here. All of our go-to-market playbooks are available on our Digital Health Builders page.
-
"There is a revolution unfolding in biotech. The confluence of new biological methods like CRISPR, virtually unlimited computational capacity, and machine learning has fundamentally transformed our ability to engineer biology for wide-ranging applications."
Vijay Pande, founding general partner at a16z Bio + Health, joins the Software Engineering Daily podcast to talk about innovation in biotech and healthcare, the biotech startup landscape, the impact of AI, and much more.
You can see a transcript of the episode and more information about Software Engineering Daily here.
-
Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.
Together, they discuss Rosana and Marty's recent publication regarding a virus-like element in our genome known as LINE-1. LINE-1, part of our "dark genome," was ignored as junk DNA for years, but is increasingly recognized to contribute to the pathology of autoimmunity, cancer, neurodegeneration, and aging. Rosana and Marty discuss how the discovery was made as well as how Rome Therapeutics is developing a platform to target LINE-1 and other factors that are part of the "dark genome" for the treatment of disease.
Additional reading:
Structures, functions and adaptations of the human LINE-1 protein -
Vijay Pande, founding partner of a16z Bio + Health, dives deep with a16z Podcast host Steph Smith into the potential of DNA as a data storage mechanism.
This episode, a cross-post with the a16z Podcast, draws parallels between Moore's Law and the race for "Moore's Law for DNA." Vijay discusses the density, longevity, and ubiquity of DNA, and how this could be leveraged into a data storage solution. Vijay and Steph mix technical advancements with futuristic speculation as they talk about what the future of biotech might look like.
-
Julie Klapstein, founding CEO of Availity, long-time healthcare executive, and a16z Bio + Health's newest advisory partner, joins Julie Yoo, general partner at a16z Bio + Health.
Together, they delve into Julie Klapstein's rich career journey, which has spanned several decades of progress in healthcare. They also discussed building Availity, her time at MultiPlan, and the network effects undergirding both businesses. Finally, they talk about how AI could impact healthcare—for payors, providers, and the network businesses in between.
-
Scribe Therapeutics cofounder and CEO Benjamin Oakes, PhD, joins a16z Bio + Health founding general partner Vijay Pande.
In this episode, Benjamin traces his journey from PhD student to pioneering CEO in genome editing. Benjamin discusses his early exposure to CRISPR technologies, his hands-on experience of transforming these bacterial immune systems into "genome editing scalpels," and the founding of Scribe. The conversation sheds light on the challenges of engineering these molecules, as well as the potential for life-changing therapeutics.
-
Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health.
In this episode, engineer-turned-entrepreneur Josh charts his journey from SpaceX and Hyperloop to cofounding metabolic health-focused company Levels. With a relentless drive for data-led health monitoring, Josh highlights the potential of wearable tech for tracking various biomarkers. Josh, Vijay, and Daisy also discuss how AI can simplify complex wearables data into a comprehensible and actionable health profile, with the potential to democratize healthcare technology.
-
Former gymnast and current investor Aly Raisman joins general partner Julie Yoo and investment partner Daisy Wolf of a16z Bio + Health.
In this episode, Aly Raisman shares her quest for healthier living—physically, mentally and financially—on her journey from gymnast to a business investor. Having herself transitioned from an intensely structured routine, Aly emphasizes the need for more open conversations about mental health and financial literacy. She speaks passionately about the gap in women’s health solutions and hopes to inspire entrepreneurs to create impactful businesses. Aly’s experiences as a patient, survivor, and global figure adds a unique dimension to her perspective as an investor. This candid conversation with both Aly and Julie Yoo sheds light on Aly’s passion for more education within the investment space offering invaluable insights for entrepreneurs, particularly in biotech and healthcare.
-
Max Cohen, cofounder and CEO of Sprinter Health, and Eren Bali, founder and CEO of Carbon Health, join Julie Yoo, general partner at a16z Bio + Health.
Together, they talk about becoming healthcare entrepreneurs despite non-healthcare backgrounds and what they had to learn along the way. They also discuss finding product-market fit, how they track PMF using KPIs, and the evolving investor landscape as the digital health space expands and matures.
Additional reading:
Digital Health Builder Diaries series -
In this episode, Joe Grogan, a senior fellow at the Leonard D. Schaeffer Center for Health Policy and Economics and a former senior government official, joins Vijay Pande, founding partner of a16z Bio + Health to discuss all things regulation.
Together, they dive into Joe’s experience working in the early days of the Covid pandemic, how he thinks about the Inflation Reduction Act’s effect on pharmaceutical R&D, and the future of AI regulation.
Additional reading:
Check out Joe's latest op-ed here, his own podcast here, and his Twitter account here.
-
Today's episode features the CEO of Tome Biosciences, Rahul Kakkar, alongside John Finn, CSO of Tome. They are joined by Jorge Conde, general partner at a16z Bio + Health.
Together, the three of them discuss the technology underlying Tome's work, known as PASTE, a genome editing technique. They also dive deep into how this technology could be applied to help patients, making cell therapy more accessible for more people.
Editorial note: We mistakenly identified Rahul Kakkar and John Finn as the co-founders of Tome Biosciences. In reality, Rahul serves as the CEO, and John is the CSO of Tome. The actual co-founders of Tome Biosciences are Jonathan Gootenberg and Omar Abudayyeh.
-
Bio Eats World is now Raising Health!
Vijay Pande, founding partner of Bio + Health, is joined by Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit.
Vijay leads us on a reflective journey through the monumental achievements in AI from the 1980s to today, with a focus on the progress in healthcare and life sciences. This episode is drawn from the episodes we recorded in 2023 with Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit, which are linked below.
This blend of expert commentary and firsthand insights explores the burgeoning impact of AI on healthcare innovation and how it's reshaping the future of health.
AI and Actionable Insights for Drug Development with Daphne KollerNavigating the Future of AI with Andrew NgWhen Quantity Becomes Quality with Aviv RegevUsing AI to Take Bio Farther with Jakob Uszkoreit -
Bio Eats World is now Raising Health!
On this first episode of Raising Health, Sean Duffy, cofounder and CEO of Omada Health, joins Vijay Pande, founding partner of Bio + Health.
Sean and Vijay discuss the building and growth of Omada, from the early days to now. As the cofounder of one of the original digital health companies, Sean has unique insight into the growth of both the digital health field and the changing venture capital environment. They also talk about the future of AI, how Omada is leveraging AI, and the challenges that might arise with using a technology in a caregiving environment.
-
Pranav Rajpurkar, PhD, joins Vijay Pande, founding partner of a16z Bio + Health.
In this episode, Pranav and Vijay discuss a future with generalist medical AI. This is the idea of a medical AI that isn’t narrowly tailored to one specific task. As Pranav notes in the episode, the research and development process in medical AI development so far has been siloed by specialty, but generalist medical AI exists outside those siloes. If generalist medical AI is successful, it could act as a dynamic support system to a physician, almost like a medical resident.
- Visa fler